|
A IL-8 foi renomeada como CXCL8 polo Subcomité de Nomenclatura de Quimiocinas da [[Unión Internacional de Sociedades Inmunolóxicas]],.<ref name="pmid12433287">{{cite journal | author = Bacon K, Baggiolini M, Broxmeyer H, Horuk R, Lindley I, Mantovani A, Maysushima K, Murphy P, Nomiyama H, Oppenheim J, Rot A, Schall T, Tsang M, Thorpe R, Van Damme J, Wadhwa M, Yoshie O, Zlotnik A, Zoon K | title = Chemokine/chemokine receptor nomenclature | journal = J. Interferon Cytokine Res. | volume = 22 | issue = 10 | pages = 1067–8 | year = 2002 | pmid = 12433287 | doi = 10.1089/107999002760624305 }}</ref> O seu símbolo xénico aprobado pola [[Organización do Xenoma Humano]] (HUGO) é ''CXCL8''.
== RegulationRegulación ofda Expressionexpresión ==
TheA expressionexpresión ofde IL-8 isé negativelyregulada regulatednegativamente bypor amedio numberde ofdiversos mechanismsmecanismos. O MiRNA[[miARN]]-146a/b-5p indirectlyreprime repressesindirectamente a expresión de IL-8 expressionao bysilenciar silencinga theexpresión expression ofde IRAK1.<ref name="pmid20148189">{{vcite2cite journal | vauthorsauthor = Bhaumik D, Scott GK, Schokrpur S, Patil CK, Orjalo AV, Rodier F, Lithgow GJ, Campisi J | title = MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8 | journal = Aging (Albany NY) | volume = 1 | issue = 4 | pages = 402–11 | year = 2009 | pmid = 20148189 | pmc = 2818025 | doi = }}</ref> AdditionallyAdicionalmente, theo [[3'UTR]] ofde IL-8 containscontén aun A/U-rich[[elemento elementrico thaten makesAU]], itque extremelyo unstablefai underextremadamente certaininestable conditionsbaixo certas condicións. A expresión de IL-8 expressionestá istamén alsoregulada regulatedpolo by[[factor thede transcription factortranscrición]] [[NF-κB]].<ref name="RottnerFreyssinet2009">{{vcite2cite journal | vauthorsauthor = Rottner M, Freyssinet JM, Martínez MC | title = Mechanisms of the noxious inflammatory cycle in cystic fibrosis | journal = Respir. Res. | volume = 10 | issue = 1 | pages = 23 | year = 2009 | pmid = 19284656 | doi = 10.1186/1465-9921-10-23 }}</ref> A regulación polo [[NF-κB]] regulationrepresenta representsunha a novelterapia anti-IL-8 therapynova forpara useo inseu inflammatoryuso diseasesen suchdoenzas asinflamatorias cysticcomo fibrosisa [[fibrose quística]].
== See also ==
|
